You are here: Industry Insights > PD-1

News List

Has the booming PD-1 inhibitor reached its limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Next Stop for PD-1? MNC for Subcutaneous Preparation Takes the Lead in Competition, Leading to A More Fierce Domestic Conpetition, but Differentiation is not easy Spur 203/PharmaSources
December 14, 2023
The competition for the subcutaneous formulation of PD-1/PD-L1 inhibitors has been spreading globally for a long time, with Roche and Bristol Myers Squibb currently leading the pack.
PD-1 Inhibitor Combined with ADC, the Strong Cooperation of Innovent and Remegen Far-away from the Crowd/PharmaSources
July 25, 2023
Recently, Innovent and Remegen will carry out a clinical research cooperation on the combination of Sintilimab Injection, a PD-1 inhibitor, with RC88, a novel antibody-drug conjugate targeting MSLN, and RC108, a novel ADC targeting c-MET, res.
Innovent's PD-1 suffered setbacks in the listing of overseas market, a paradigm for Chinese innovative drug in the global market PharmaSources/Caicai
February 22, 2022
Recently, FDA held an ODAC (Oncologic Drugs Advisory Committee) meeting around the key event in the listing application of Sintilimab, Innovent's PD-1 monoclonal antibody, in the United States.
In 2021, the sales volume of Innovent's PD-1 exceeded RMB 3 billion PharmaSources/Caicai
February 21, 2022
Chinese PD-1 also sells well. According to the quarterly sales data of Innovent's sintilimab (trade name: Tyvyt), its sales volume was about RMB 3.1 billion in 2021 (nominal sales revenue).
Human trial data of oral small molecule PD-1/PD-L1 inhibitors were first released PharmaSources/Xiaoyaowan
December 02, 2021
Recently, Incyte of the United States reported the Phase I clinical data of oral small molecule PD-L1 inhibitor INCB086550 in Journal for ImmunoTherapy of Cancer.
Penpulimab, the Fifth Chinese PD-1 Monoclonal Antibody, was approved for Marketing PharmaSources/Yefenghong
August 25, 2021
On August 5, penpulimab (AK105) developed by Akeso, Inc. was approved for marketing, which is used to treat patients with relapsed or refractory classic Hodgkin's lymphoma (r/r cHL) after second-line systemic chemotherapy.
Junshi’s Anti-PD-1 Drug Achieved Sales of RMB1.3 Billion in 2020 PharmaSources/Caicai
March 12, 2021
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.
Production Applications of Chinese New Drugs in 2020 H1: Five Class 1 New Chemical Drugs, Two Anti-PD-1 Monoclonal Antibodies and Two CAR T-Cell Products Applied for Production for the First Time PharmaSources/Dopine
December 24, 2020
According to the Insight database, the CDE generated 50 marketing application acceptance numbers for Chinese new drugs in 2020 H1,...
PK Hengrui! New indication of Merck's PD-1 monoclonal antibody Keytruda esophageal cancer is about to be approved in China CPhI.CN
June 17, 2020
New indication of Merck's PD-1 monoclonal antibody Keytruda esophageal cancer is about to be approved in China